Type to search

Prime Therapeutics and Pear Therapeutics Announce First Comprehensive Value-based Agreement for Prescription Digital Therapeutics reSET® and reSET-O® for the Treatment of Substance and Opioid Use Disorders | Pharmtech Focus
Prime Therapeutics Welcomes Chris Knibb as Chief Financial Officer | Pharmtech Focus